No. of Recommendations: 1
I'm with Digger65

There are lots of cases where a small molecule can't replace a protein. For example, the mechanism of action of monoclonal antibodies which are having a big surge of late (e.g. MLNM's Campath or BGEN's hepatitis B vaccine)couldn't be replaced by a small molecule (as far as I can imagine).

I would also add that the "ultimate goal" (as described by beachbum10) should include the stipulation of an orally available small molecule. Finding a peptide mimetic is a challenge in and of itself but making one that is orally bioavailable is an additional major challenge. However, therein lies the profit advantage over a protein therapeutic. Orally available drugs are in general: cheaper to make and much preferred by patients.

Good Board

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.